Cargando…

Clinical Performance of Oral Anticoagulants in Elderly with Atrial Fibrillation and Low Body Weight: Insight into Italian Cohort of PREFER-AF and PREFER-AF Prolongation Registries

Background: Elderly patients are at high risk of both ischaemic and bleeding events, and the low body weight is considered a risk factor for major bleeding in atrial fibrillation (AF) patients on anticoagulation therapy. The aim of our study was to compare the safety and effectiveness of non-vitamin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Russo, Vincenzo, Attena, Emilio, Baroni, Matteo, Trotta, Roberta, Manu, Marius Constantin, Kirchhof, Paulus, De Caterina, Raffaele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267647/ https://www.ncbi.nlm.nih.gov/pubmed/35807032 http://dx.doi.org/10.3390/jcm11133751

Ejemplares similares

Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry
por: Schnabel, Renate B, et al.
Publicado: (2023)

Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry
por: Boriani, Giuseppe, et al.
Publicado: (2021)

Heterogeneity of outcomes within diabetic patients with atrial fibrillation on edoxaban: a sub-analysis from the ETNA-AF Europe registry
por: Patti, Giuseppe, et al.
Publicado: (2022)

Perceived vs. objective frailty in patients with atrial fibrillation and impact on anticoagulant dosing: an ETNA-AF-Europe sub-analysis( )
por: Diemberger, Igor, et al.
Publicado: (2022)

Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF)
por: Rohla, Miklos, et al.
Publicado: (2019)

Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry
por: Renda, Giulia, et al.
Publicado: (2020)

Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events—European Registry in Atrial Fibrillation (PREFER in AF)
por: Kirchhof, Paulus, et al.
Publicado: (2014)

Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub‐Analysis From the PREFER in AF (PREvention oF Thromboembolic Events–European Registry in Atrial Fibrillation)
por: Patti, Giuseppe, et al.
Publicado: (2017)

Can we improve outcomes in AF patients by early therapy?
por: Kirchhof, Paulus
Publicado: (2009)

Predictors of intracranial hemorrhage in patients with atrial fibrillation treated with oral anticoagulants: Insights from the GARFIELD‐AF and ORBIT‐AF registries
por: Lim, Toon Wei, et al.
Publicado: (2023)

Use of Oral Anticoagulants in Patients with Atrial Fibrillation: Preliminary Data from the Italian Atrial Fibrillation (ITALY-AF) Registry
por: Angeli, Fabio, et al.
Publicado: (2023)

Indonesian registry on atrial fibrillation (OneAF)
por: Raharjo, Sunu Budhi, et al.
Publicado: (2021)

Predictors for Stroke and Death in Non-Anticoagulated Asian Patients with Atrial Fibrillation: The Fushimi AF Registry
por: Hamatani, Yasuhiro, et al.
Publicado: (2015)

Anticoagulation in patients with atrial fibrillation and heart failure: Insights from the NCDR PINNACLE‐AF registry
por: Contreras, Johanna P., et al.
Publicado: (2019)

Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF)
por: Steinberg, Benjamin A, et al.
Publicado: (2015)

Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)
por: De Caterina, Raffaele, et al.
Publicado: (2019)

Spironolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESS‐AF Trial
por: Shantsila, Eduard, et al.
Publicado: (2020)

Current use of direct oral anticoagulants for atrial fibrillation in Japan: Findings from the SAKURA AF Registry
por: Okumura, Yasuo, et al.
Publicado: (2017)

Oral Anticoagulation Therapy in Atrial Fibrillation Patients with Advanced Chronic Kidney Disease: CODE-AF Registry
por: Park, Hanjin, et al.
Publicado: (2023)

Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation: One-Year Data from the Global ETNA-AF Program
por: Chao, Tze-Fan, et al.
Publicado: (2023)

Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study
por: de Groot, Joris R, et al.
Publicado: (2020)

AFS Monitoring: The CERN AFS Console
por: Wiebalck, Arne
Publicado: (2008)

Changes in anticoagulant prescription in Dutch patients with recent-onset atrial fibrillation: observations from the GARFIELD-AF registry
por: Seelig, J., et al.
Publicado: (2020)

Twelve-month outcome in patients with stroke and atrial fibrillation not suitable to oral anticoagulant strategy: the WATCH-AF registry
por: Guidoux, Celine, et al.
Publicado: (2019)

AF in Cancer Patients: A Different Need for Anticoagulation?
por: Sanz, Ana Pardo, et al.
Publicado: (2019)

The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF): Exploring the changes in anticoagulant practice in patients with non-valvular atrial fibrillation in the Netherlands
por: ten Cate, V., et al.
Publicado: (2016)

Mug{AF}amar{AF}at Farn{AF}ats{AF}i == Farnatchi au bal masqué == Farnatchi at the masked ball /
por: Fayard, Roland
Publicado: (1997)

Evaluation of the vascular protective effects of new oral anticoagulants in high-risk patients with atrial fibrillation (PREFER-AF): study protocol for a randomized controlled trial
por: Kim, Jin-Bae, et al.
Publicado: (2016)

Impact of different anticoagulation management strategies on outcomes in atrial fibrillation: Dutch and Belgian results from the GARFIELD‐AF registry
por: Seelig, Jaap, et al.
Publicado: (2020)

Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD‐AF Registry
por: Cools, Frank, et al.
Publicado: (2021)

Determinants and clinical outcomes of patients who refused anticoagulation: findings from the global GARFIELD-AF registry
por: Apenteng, Patricia, et al.
Publicado: (2023)

Erratum to: The Global Anticoagulant Registry in the FIELD – Atrial Fibrillation (GARFIELD-AF): Exploring the changes in anticoagulant practice in patients with non-valvular atrial fibrillation in the Netherlands
por: ten Cate, V., et al.
Publicado: (2016)

Overophedning af partikelaccelerator var frygtet af forskere
Publicado: (2008)

Symptomatic and Asymptomatic Patients in the Polish Atrial Fibrillation (POL-AF) Registry
por: Kiliszek, Marek, et al.
Publicado: (2021)

Age-dependent risk for thromboembolism in atrial fibrillation: The Fushimi AF registry
por: Esato, Masahiro, et al.
Publicado: (2022)

Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program
por: De Caterina, Raffaele, et al.
Publicado: (2021)

A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial
por: Kotecha, Dipak, et al.
Publicado: (2017)

Anticoagulation Therapy by Age and Embolic Risk for Nonvalvular Atrial Fibrillation in Mexico, an Upper-Middle-Income Country: The CARMEN-AF Registry
por: Márquez, Manlio F., et al.
Publicado: (2020)

Global Oral Anticoagulation Use Varies by Region in Patients With Recent Diagnosis of Atrial Fibrillation: The GLORIA‐AF Phase III Registry
por: Bayer, Valentina, et al.
Publicado: (2022)

Trends in the Prescription of Non-Vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation: Results of the Polish Atrial Fibrillation (POL-AF) Registry
por: Gorczyca, Iwona, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pu4qm9mh2q02o5885kicj0924s